Assays that detect hepatitis C, hepatitis C genotyping, and human immunodeficiency virus are now commercially available in countries accepting the CE mark.
Cologuard is designed to be patient- and physician-friendly, and is highly automated to support efficiencies in Exact Sciences' lab.
Exact Sciences overcame significant obstacles to bring cancer screening innovation to patients.
The DiscoveryMap platform from Myriad RBM has identified combinations of 15 protein biomarkers associated with cardiovascular events in patients with diabetes.
Idex Health & Science has launched a newly expanded portfolio of fluidic, microfluidic, and optical components and capabilities.
Four transplant centers are participating in an early access program for the company’s blood test for kidney transplant recipients.
The allergen component tests by Thermo Fisher Scientific detect immunoglobulin E sensitization to hazelnut, walnut, and cashew nut proteins.
Under a nonexclusive agreement, Henry Schein will market Cepheid’s GeneXpert system to its non-acute care laboratory customers in the United States.
In partnership with biopharmaceutical companies, Leica Biosystems and Advanced Cell Diagnostics are collaborating to develop and commercialize fully automated RNAscope-based companion diagnostics.
With the acquisition, Abbott gains leadership in the $5.5 billion point-of-care segment, broadens its diagnostics footprint, and enhances access to fast-growing diagnostics channels.
This month's Product News includes focused gene expression panels, a cystatin C assay, a supply and procedure cart system, and a modular embedding system.
The company recently received ethical approval to commence a 6-month clinical study using its urine test for cancer.
Named Grail, the business seeks to enable early cancer detection via blood-based screening.
The companies have partnered to develop a comprehensive next-generation sequencing workflow for single-cell analyses.
GenomeDx Biosciences recently presented first validation data supporting the use of its Decipher test to help guide the treatment of men newly diagnosed with prostate cancer.
Acquisition gives PE access to an innovative noninvasive prenatal testing solution under development, expanding the company’s maternal–fetal health portfolio.
Lab professionals can expect that flow cytometry will continue to evolve in new directions with even greater utility for clinical testing.
The company reports that clinical trials using its MosaiQ transfusion diagnostic instrument and associated assays will begin later this year.
After closing $32 million in private equity financing, molecular diagnostics unit bioTheranostics will operate as an independent company.
Royal Philips and Banyan Biomarkers have entered into a multiyear agreement to jointly develop and commercialize a handheld blood test for detecting and evaluating mild traumatic brain injury.